No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of the European Academy of Dermatology and Venereology : JEADV - 34(2020), 9 vom: 21. Sept., Seite e433-e434 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carugno, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
420K487FSG |
|---|
| Anmerkungen: |
Date Completed 06.01.2021 Date Revised 20.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jdv.16552 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309234220 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309234220 | ||
| 003 | DE-627 | ||
| 005 | 20231225133448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jdv.16552 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309234220 | ||
| 035 | |a (NLM)32339362 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carugno, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2021 | ||
| 500 | |a Date Revised 20.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Interleukin-4 Receptor alpha Subunit |2 NLM | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 700 | 1 | |a Raponi, F |e verfasserin |4 aut | |
| 700 | 1 | |a Locatelli, A G |e verfasserin |4 aut | |
| 700 | 1 | |a Vezzoli, P |e verfasserin |4 aut | |
| 700 | 1 | |a Gambini, D M |e verfasserin |4 aut | |
| 700 | 1 | |a Di Mercurio, M |e verfasserin |4 aut | |
| 700 | 1 | |a Robustelli Test, E |e verfasserin |4 aut | |
| 700 | 1 | |a Sena, P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the European Academy of Dermatology and Venereology : JEADV |d 1997 |g 34(2020), 9 vom: 21. Sept., Seite e433-e434 |w (DE-627)NLM091705932 |x 1468-3083 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:9 |g day:21 |g month:09 |g pages:e433-e434 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jdv.16552 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 9 |b 21 |c 09 |h e433-e434 | ||